Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFIRINOX as second-line chemotherapy for advanced biliary tract cancer
KCT0004433Phase 2Active, not recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Dec 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, irinotecan, oxaliplatin in biliary cancer, gallbladder cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA), sponsored by Samyang Biopharmaceuticals Corporation. Started Dec 2019; status: active, not recruiting.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatin
03
Conditions
biliary cancergallbladder cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on KCT0004433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004433.